000			nab a22 7a 4500
999			_c17883 _d17883
003			PC17883
005			20240624140402.0
008			240624b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91945 _aGonzalo Gil, Elena _eReumatología
100			_92652 _aPérez Lorenzo, María J. _eInstituto de Investigación i+12
100			_9466 _aGalindo Izquierdo, María _eReumatología
100			_91010 _aPablos Álvarez, José Luis _eReumatología
100			_91880 _aCriado Carrasco, Gabriel _eInstituto de Investigación i+12
245	0	0	_aHuman embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase. _h[artículo]
260			_bArthritis research and therapy, _c2016
300			_a18:77.
500			_aFormato Vancouver: Gonzalo Gil E, Pérez Lorenzo MJ, Galindo M, Díaz de la Guardia R, López Millán B, Bueno C et al. Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase. Arthritis Res Ther. 2016 Apr 1;18:77.
501			_aPMID: 27036118 PMC4818397
504			_aContiene 48 referencias
520			_aBackground: The immunosuppressive and anti-inflammatory properties of mesenchymal stromal cells (MSC) have prompted their therapeutic application in several autoimmune diseases, including rheumatoid arthritis. Adult MSC are finite and their clinical use is restricted by the need for long-term expansion protocols that can lead to genomic instability. Inhibition of Smad2/3 signaling in human pluripotent stem cells (hPSC) provides an infinite source of MSC that match the phenotype and functional properties of adult MSC. Here, we test the therapeutic potential of hPSC-MSC of embryonic origin (embryonic stem cell-derived mesenchymal stromal cells, hESC-MSC) in the experimental model of collagen-induced arthritis (CIA). Methods: CIA was induced in DBA/1 mice by immunization with type II collagen (CII) in Complete Freund's Adjuvant (CFA). Mice were treated with either a single dose (10(6) cells/mouse) of hESC-MSC on the day of immunization (prophylaxis) or with three doses of hESC-MSC every other day starting on the day of arthritis onset (therapy). Arthritis severity was evaluated daily for six weeks and ten days, respectively. Frequency of Treg (FoxP3(+)), Th1 (IFNγ(+)) and Th17 (IL17(+)) CD4(+) T cells in inguinal lymph nodes (ILN) was quantified by flow cytometry. Serum levels of anti-CII antibodies were determined by ELISA. Detection of hESC-MSC and quantification of murine and human indoleamine 2,3 dioxygenase (IDO1) expression was performed by quantitative real-time PCR. Statistical differences were analyzed by ANOVA and the Mann-Whitney U test. Results: Administration of hESC-MSC to mice with established arthritis reduced disease severity compared to control-treated mice. Analysis of CD4 T cell populations in treated mice showed an increase in FoxP3(+) Treg and IFNγ(+) Th1 cells but not in Th17 cells in the ILN. Anti-CII antibody levels were not affected by treatment. Migration of hESC-MSC to the ILN in treated mice was associated with the induction of murine IDO1.
710			_9625 _aInstituto de Investigación imas12
710			_9123 _aServicio de Reumatología
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818397/ _yAcceso libre
942			_2ddc _cART _n0